Palvella Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2015-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.palvellatx.com
Clinical Trials
8
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations
- Conditions
- Cutaneous Venous Malformations
- Interventions
- First Posted Date
- 2024-10-22
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Palvella Therapeutics, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT06653842
- Locations
- 🇺🇸
Children's Hospital of Orange County, Irvine, California, United States
🇺🇸Colorado Children's Hospital, Aurora, Colorado, United States
🇺🇸John's Hopkins, Baltimore, Maryland, United States
SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations
- Conditions
- Microcystic Lymphatic Malformation
- Interventions
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Palvella Therapeutics, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06239480
- Locations
- 🇺🇸
Children's Hospital of Orange County, Irvine, California, United States
🇺🇸University of Utah Health, Salt Lake City, Utah, United States
🇺🇸Stanford University, Palo Alto, California, United States
A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2022-12-09
- Lead Sponsor
- Palvella Therapeutics, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT05643872
- Locations
- 🇺🇸
Minnesota Clinical Study Center, New Brighton, Minnesota, United States
A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita
- Conditions
- Pachyonychia Congenita
- Interventions
- Drug: Vehicle
- First Posted Date
- 2022-01-06
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Palvella Therapeutics, Inc.
- Target Recruit Count
- 87
- Registration Number
- NCT05180708
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸Yale University, New Haven, Connecticut, United States
🇺🇸Park Avenue Dermatology, Orange Park, Florida, United States
Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations
- First Posted Date
- 2021-09-20
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Palvella Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT05050149
- Locations
- 🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸Stanford University, Palo Alto, California, United States
🇺🇸Minnesota Clinical Study Center, Fridley, Minnesota, United States
- Prev
- 1
- 2
- Next